MPN Hub

The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.

MPN Hub is a education podcast hosted by Scientific Education Support, with 25 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Scientific Education Support hosts MPN Hub, a education show with 25 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  MPN Hub

  Symposium | Advanced systemic mastocytosis: Therapeutic landscape: Evidence-based strategies across the disease spectrum

  Aug 3, 202616 min

  At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Alessandro Vannucchi, University of Florence, Florence, IT, discussed evidence-based treatment strategies across the disease spectrum of advanced systemic mastocytosis (AdvSM).    In this presentation, Vannucchi reviews the evolving therapeutic landscape in AdvSM, highlighting considerations that influence treatment selection across disease subtypes. Vannucchi discusses historical and contemporary treatment approaches, clinical evidence for KIT-targeted therapies, evolving goals for treatment, and emerging therapeutic strategies that may further inform future clinical management. Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  MPN Hub

  Symposium | Looking ahead: Future directions and unanswered questions in AdvSM

  Aug 2, 202625 min

  At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes.     The symposium closed with a panel Q&A session with live audience participation. The panelists, Deepti H Radia, Andreas Reiter, Johannes Lübke, and Alessandro Vannucchi, discussed key challenges in advanced systemic mastocytosis (AdvSM), including underdiagnosis and complexities in the management of SM with an associated hematologic neoplasm (AHN), and mast cell leukemia (MCL). They also discussed emerging combination therapies and highlighted allogeneic hematopoietic stem cell transplantation (allo-HSCT) as the only potentially curative option in AdvSM, emphasizing the importance of optimal disease control prior to transplantation. Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  MPN Hub

  Symposium | Advanced systemic mastocytosis: Diagnosis, risk stratification, and response assessment in 2026

  Jul 30, 202617 min

  At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Johannes Lübke, University Hospital Mannheim, Mannheim, DE, delivered a presentation on diagnosis, risk stratification, and response assessment in advanced systemic mastocytosis (AdvSM).    Lübke discusses the current diagnostic framework for systemic mastocytosis, emphasizing the need for integrated disease assessment beyond established diagnostic criteria. He explores the role of molecular profiling in prognostic risk stratification, evolving prognostic models in the era of KIT-targeted therapy, current and emerging approaches to response assessment, and the complementary role of patient-reported outcomes in evaluating disease burden and treatment benefit. This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  MPN Hub

  Targeting KIT in advanced systemic mastocytosis

  Jul 27, 202626 min

  During the MPN Hub Steering Committee Meeting in May 2026, Andreas Reiter, University Hospital Mannheim, Mannheim, DE, delivered a presentation on targeting KIT in advanced systemic mastocytosis (AdvSM). In this presentation, Reiter discusses the rationale for KIT inhibition, and key efficacy and safety data for KIT-targeting therapies in AdvSM. The presentation highlights data from key trials, including the depth of molecular response with KIT-targeting therapies and its correlation with clinical benefit, and concludes with an overview of future directions in KIT inhibition for patients with AdvSM.  This educational resource is independently supported by Blueprint Medicines. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.   Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  MPN Hub

  Symposium | Advanced systemic mastocytosis: Clinical challenges and unmet needs

  Jul 23, 202617 min

  At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Andreas Reiter, University Hospital Mannheim, Mannheim, DE, delivered a presentation on clinical challenges and unmet needs in advanced systemic mastocytosis (AdvSM).    In this presentation, Reiter discusses how genetic complexity underpins disease heterogeneity and clinical presentation in AdvSM, how variable disease presentation can lead to diagnostic delays, and that treatment outcomes highlight variability across AdvSM subtypes. He explores the limitations of conventional disease burden assessment, the variable symptom burden impacts on quality of life across systemic mastocytosis (SM) subtypes, and how disease heterogeneity can lead to complexity in AdvSM management. In addition, he discusses the variability in morphology and genetics in SM with an associated hematologic neoplasm, and illustrates potential challenges in clinical practice using a patient case study.  This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.   Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes

Recent guests on MPN Hub. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.